HC Q study #98
See all studies
Pre-Exposure Prophylaxis study (treated before exposed to the virus)
Rentsch et al., medRxiv, doi:10.1101/2020.09.04.20187781 (Preprint)
Hydroxych loroquine for prevention of COVID-19 mortality: a population-based cohort study
Observational database study of RA/SLE patients in the UK, 194,637 RA/SLE patients with 30,569 having >= 2 HC Q prescriptions in the prior 6 months, HC Q HR 1.03 [0.80-1.33] (HR 0.78 before adjustments).
70 patients with HC Q prescriptions died. One major problem is that there is no knowlege of medication adherence for these 70 - for example, it is possible that they were part of the expected percentage of patients that did not take the medication as prescribed, invalidating the result.
Both confirmed and suspected deaths were included. It is not clear why the authors did not report the result for only confirmed cases. It has been reported that several thousand deaths were incorrectly declared as COVID-19 in the UK.
Other limitations: confounding by use of bDMARDs, confounding by severity of rheumatological disease.
Source   Share   Tweet
See all studies
Please send us corrections, updates, or comments.